RSPN vs. BIS
RSPN (Invesco S&P 500® Equal Weight Industrials ETF) and BIS (ProShares UltraShort Nasdaq Biotechnology) are both exchange-traded funds - RSPN is a Industrials Equities fund tracking the S&P 500® Equal Weight Industrials Index, while BIS is a Leveraged Equities fund tracking the NASDAQ Biotechnology Index (-200%). Both are passively managed. Over the past 10 years, RSPN returned 14.49%/yr vs -24.02%/yr for BIS. Their -0.51 correlation means they have often moved in opposite directions in the past. RSPN charges 0.40%/yr vs 0.95%/yr for BIS.
Performance
RSPN vs. BIS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RSPN achieves a 11.17% return, which is significantly higher than BIS's -24.85% return. Over the past 10 years, RSPN has outperformed BIS with an annualized return of 14.49%, while BIS has yielded a comparatively lower -24.02% annualized return.
RSPN
- 1D
- 0.53%
- 1M
- -2.05%
- 6M
- 4.96%
- YTD
- 11.17%
- 1Y
- 16.51%
- 3Y*
- 15.49%
- 5Y*
- 11.67%
- 10Y*
- 14.49%
- ALL TIME*
- 11.48%
BIS
- 1D
- 3.65%
- 1M
- 9.65%
- 6M
- -20.75%
- YTD
- -24.85%
- 1Y
- -53.59%
- 3Y*
- -27.87%
- 5Y*
- -15.63%
- 10Y*
- -24.02%
- ALL TIME*
- -32.48%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $67.10K | $102.51K | $113.13K | |
| $7.22M | $5.89M | $7.57M |
RSPN vs. BIS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RSPN Invesco S&P 500® Equal Weight Industrials ETF | 11.17% | 13.84% | 17.63% | 22.32% | -8.79% | 26.07% | 18.07% | 33.17% | -13.23% | 23.22% |
BIS ProShares UltraShort Nasdaq Biotechnology | -24.85% | -45.95% | 4.79% | -6.54% | -2.14% | -14.74% | -56.01% | -41.01% | 5.14% | -36.98% |
Correlation
The correlation between RSPN and BIS is -0.40, meaning they have often moved in opposite directions in the past. This relationship can weaken or reverse as market conditions change.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | -0.40 |
Correlation (3Y) Balances recent behavior with more history. | -0.53 |
Correlation (5Y) Shows whether the relationship held over a longer period. | -0.53 |
Correlation (10Y) Provides a long-term view across more market conditions. | -0.49 |
Correlation (All Time) Calculated using the full available price history since Apr 8, 2010 | -0.51 |
The correlation between RSPN and BIS shifts across timeframes, from -0.53 (5 years) to -0.40 (1 year), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RSPN vs. BIS — Risk / Return Rank
RSPN
BIS
RSPN vs. BIS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco S&P 500® Equal Weight Industrials ETF (RSPN) and ProShares UltraShort Nasdaq Biotechnology (BIS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RSPN | BIS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.23 | ||
| Sortino ratioReturn per unit of downside risk | +3.56 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 0.76 | +0.40 |
| Calmar ratioReturn relative to maximum drawdown | 1.18 | -0.91 | +2.09 |
| Martin ratioReturn relative to average drawdown | 4.03 | -1.38 | +5.41 |
Loading charts...
Drawdowns
RSPN vs. BIS - Drawdown Comparison
The maximum RSPN drawdown since its inception was -59.61%, smaller than the maximum BIS drawdown of -99.89%. Use the drawdown chart below to compare losses from any high point for RSPN and BIS.
Loading charts...
Drawdown Indicators
| RSPN | BIS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -59.61% | -99.89% | +40.28% |
Max Drawdown (1Y)Largest decline over 1 year | -12.36% | -59.49% | +47.13% |
Max Drawdown (3Y)Largest decline over 3 years | -20.89% | -73.96% | +53.07% |
Max Drawdown (5Y)Largest decline over 5 years | -21.88% | -80.19% | +58.31% |
Max Drawdown (10Y)Largest decline over 10 years | -42.02% | -95.82% | +53.80% |
Current DrawdownCurrent decline from peak | -2.50% | -99.88% | +97.38% |
Average DrawdownAverage peak-to-trough decline | -7.63% | -90.11% | +82.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.62% | 39.26% | -35.64% |
Volatility
RSPN vs. BIS - Volatility Comparison
The current volatility for Invesco S&P 500® Equal Weight Industrials ETF (RSPN) is 4.54%, while ProShares UltraShort Nasdaq Biotechnology (BIS) has a volatility of 12.40%. This indicates that RSPN experiences smaller price fluctuations and is considered to be less risky than BIS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RSPN | BIS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 4.54% | 12.40% | -7.86% |
Volatility (6M)Calculated over the trailing 6-month period | 12.97% | 31.89% | -18.92% |
Volatility (1Y)Calculated over the trailing 1-year period | 16.33% | 40.71% | -24.38% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 18.28% | 43.93% | -25.65% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.34% | 46.15% | -25.81% |
RSPN vs. BIS - Expense Ratio Comparison
RSPN has a 0.40% expense ratio, which is lower than BIS's 0.95% expense ratio.
Dividends
RSPN vs. BIS - Dividend Comparison
RSPN's dividend yield for the trailing twelve months is around 0.83%, less than BIS's 5.61% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIS ProShares UltraShort Nasdaq Biotechnology | 5.61% | 5.25% | 3.73% | 1.75% | 0.00% | 0.00% | 0.45% | 2.11% | 0.37% | 0.00% | 0.00% | 0.00% |
RSPN Invesco S&P 500® Equal Weight Industrials ETF | 0.83% | 0.86% | 0.98% | 1.06% | 1.09% | 0.70% | 0.96% | 1.33% | 1.49% | 1.12% | 1.31% | 1.51% |
Frequently Asked Questions
RSPN and BIS have a correlation of -0.40, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BIS has higher volatility (12.40%) compared to RSPN (4.54%). In terms of maximum drawdown, RSPN dropped -59.61% vs BIS's -99.89%.
On 10-year performance, RSPN leads with 14.49% vs -24.02% for BIS. On fees, RSPN is cheaper at 0.40% per year. On volatility, RSPN has been the lower-risk option at 4.54%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, RSPN has performed better with a 14.49% return vs -24.02%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
RSPN is cheaper with a 0.40% expense ratio, compared with 0.95% for BIS.
BIS has the higher dividend yield at 5.61%, compared with 0.83% for RSPN.
RSPN is categorized as Industrials Equities, while BIS is Leveraged Equities. RSPN tracks S&P 500® Equal Weight Industrials Index, while BIS tracks NASDAQ Biotechnology Index (-200%). They also come from different issuers: Invesco and ProShares. Their fees differ too: 0.40% for RSPN and 0.95% for BIS.
RSPN currently has the higher Sharpe Ratio (0.89 vs -1.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RSPN and BIS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer